Does Dr. FOLUSO ADEMUYIWA have financial conflicts of interest?

Dr. FOLUSO ADEMUYIWA (MD) has received a total of $29,466 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $29,466 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. FOLUSO ADEMUYIWA?

According to CMS Open Payments data, Dr. FOLUSO ADEMUYIWA received funding from GILEAD SCIENCES ($19,454), ASTRAZENECA PHARMACEUTICALS ($6,165), and GENENTECH USA ($2,280).

Does Dr. FOLUSO ADEMUYIWA receive research grants or speaking fees?

Dr. FOLUSO ADEMUYIWA has received $29,466 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. FOLUSO ADEMUYIWA

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: SAINT LOUIS, MO 63110

NPI Number: 1083875538

LIFETIME INDUSTRY VALUE

$29,466

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ADEMUYIWA is a verified Internal Medicine, Medical Oncology practitioner based in SAINT LOUIS, MO.

Between 2021 and 2024, Dr. ADEMUYIWA had an overall industry promotional and research financial footprint of $29,466 as recorded in the federal CMS Open Payments database.

$29,466 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ADEMUYIWA's primary funding source is GILEAD SCIENCES, which accounts for $19,454 (representing 66% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GILEAD SCIENCES

Rank 1

$19,454

66%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$6,165

20.9%

GENENTECH USA

Rank 3

$2,280

7.7%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.